Trials / Completed
CompletedNCT01052051
Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 2,303 (actual)
- Sponsor
- Creighton University · Academic / Other
- Sex
- Female
- Age
- 55 Years
- Healthy volunteers
- Accepted
Summary
To determine the effect of increasing serum 25(OH)D from prevailing levels with vitamin D3 supplementation, while maintaining adequate calcium intake, on incidence of all-type cancer in a population sample of healthy postmenopausal women.
Detailed description
Hypotheses: Primary: Increasing serum 25(OH)D from prevailing levels with vitamin D3 supplementation, while maintaining adequate calcium intake, will significantly decrease incidence of all-type cancer in a population sample of healthy postmenopausal women. Secondary: 1. Increasing serum 25(OH)D from prevailing levels will significantly decrease incidence of specific cancers: breast, lung, colon, myeloma, leukemia, lymphoma. 2. Increasing serum 25OHD from prevailing levels will significantly decrease incidence of other disorders, specifically hypertension, cardiovascular disease, osteoarthritis, colonic adenomas, diabetes, upper respiratory infections and falls. Specific Aims: 1. Determine the effect of supplementation with vitamin D3 on incidence of all types of cancer combined. 2. Determine in a nested-case control study the association of serum 25OHD collected at randomization and at the end of year one of study with risk of cancer over four years. 3. Sample randomly the population of healthy independently-living postmenopausal women 55 years and older from twelve adjacent rural counties in Nebraska. 4. Enroll a random sample of 2300 women into an intervention study, assign them randomly to one of two treatment groups: 1) vitamin D3 (2000 IU/d) and calcium (1500 mg/d), or 2) vitamin D3 placebo and calcium placebo, and to follow each study participant for four years. 5. Collect and store blood serum and white blood cells from every participant to test for genetic markers should the intervention be found effective in decreasing the incidence of cancer. Markers selected will be determined by the state of the science at the time of analysis. 6. Determine the effect of supplementation with calcium and vitamin D3 on incidence of specific cancers: breast, lung, colon, myeloma, leukemia, and lymphoma. 7. Determine the effect of supplementation on incidence of other disorders, specifically hypertension, cardiovascular disease, osteoarthritis, colonic adenomas, diabetes, upper respiratory infections, fractures, and falls.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Vitamin D3 | Vitamin D3 2000 IU/daily |
| DIETARY_SUPPLEMENT | Calcium carbonate | Calcium carbonate 1500mg / daily |
Timeline
- Start date
- 2009-06-01
- Primary completion
- 2015-08-01
- Completion
- 2015-08-01
- First posted
- 2010-01-20
- Last updated
- 2019-07-24
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01052051. Inclusion in this directory is not an endorsement.